T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer
SAN FRANCISCO and BERLIN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced the appointment of Simone Silva Steiner, Ph.D., to the role of Chief Technical Operations Officer.
“We are excited to welcome Simone to T-knife,” stated Thomas M. Soloway, Chief Executive Officer of T-knife. “Her impressive track-record of success in cell therapy manufacturing, analytical development and process development will be invaluable as we scale up our manufacturing activities to support the ongoing Phase 1/2 IMAG1NE study for TK-8001, our T cell receptor engineered T cell therapy specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1.”
Dr. Steiner was previously the Head of Technical Development and Manufacturing at Tigen Pharma where she led all activities related to technical development and manufacturing strategy for a TIL product. From 2010 to 2020, Dr. Steiner was in manufacturing and quality roles at Novartis, most recently as the Head of Process Unit CGT Stein where she designed and constructed a cell therapy manufacturing facility and supported the successful manufacturing of Kymriah. During her tenure, she built the company’s cell therapy production capabilities, hiring and training more than one hundred manufacturing associates. At QSV Biologics, a contract manufacturing organization, Dr. Steiner was responsible for process development for multiple projects and worked on the full renovation of QSV’s cGMP manufacturing facility. She obtained her Ph.D. at ETH Zurich and completed her post doc work at the University of Alberta.
Dr. Steiner added, “T cell receptor-based immunotherapies are a promising modality for the next generation of cancer therapeutics, and T-knife’s platform has the potential to deliver best-in-class TCR-Ts. TK-8001 has already demonstrated potent preclinical activity, and I am excited to support the advancement of this differentiated product candidate, as well as the pipeline of candidates generated from the MyT™ platform.”
About T-knife Therapeutics
T-knife is a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients. Focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), the company’s unique approach leverages its proprietary MyT™ platform, a suite of technologies to enable the advancement of next-generation TCR-Ts for solid tumor cancers.
T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens and commonly shared tumor-driving neoantigens. The company’s lead program targeting MAGE-A1 positive solid tumors is in a Phase 1/2 clinical study. T-knife was founded by leading T cell and immunology experts utilizing technology developed at the Max Delbrück Center for Molecular Medicine together with the Charité – Universitätsmedizin Berlin, and is supported by a leading group of international investors, including Andera Partners, EQT Life Sciences, RA Capital Management and Versant Ventures. For additional information, please visit the company’s website at www.t-knife.com.
T-knife Therapeutics, Inc.
Chief Business Officer / Chief Financial Officer
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Hexagon Purus awarded purchase order by Ford Trucks to deliver a hydrogen fuel storage system for their prototype heavy-duty truck7.12.2023 08:07:00 CET | Press release
(Oslo, 7 December 2023) Hexagon Purus, a world leading supplier of zero-emission infrastructure and mobility solutions, has been awarded a purchase order by Ford Trucks to deliver a complete hydrogen fuel storage system for development of a Fuel Cell Electric-Powered Vehicle (FCEV) F-MAX as part of the Horizon Europe project ZEFES (Zero Emission Freight EcoSystem), a zero-emission logistics deployment project in which Ford Trucks participates with the vision of pioneering future transportation solutions. As a partner in project ZEFES, a pan-European project specifically targeting decarbonization of long-haul heavy-duty trucking in Europe, Ford Trucks will develop and deliver a fuel cell electric heavy-duty prototype F-MAX truck that will operate as part of a larger fleet of zero-emission trucks collecting data from real-world operations. The F-MAX FCEV will be Ford Trucks’ first fuel cell-powered vehicle, developed and manufactured in Turkey, and will begin European Ten-T corridor demo
AB Akola Group: notification on disposal of voting rights7.12.2023 08:04:58 CET | Press release
AB Akola Group (former AB Linas Agro Group), ISIN code LT0000128092 (hereinafter - the Company), received notification from UAB „SB Asset Management“ on the disposal of voting rights due to the increase in the authorized capital of the Company (enclosed). Additional information: Mažvydas Šileika, CFO of AB Akola Group Mob. +370 619 19 403 E-mail email@example.com Attachment Notification-of-disposal-of-block-of-shares LNA 2023 12 06-s1206
Dividend Declaration7.12.2023 08:00:00 CET | Press release
Volta Finance Limited (VTA/VTAS) Dividend Declaration NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Guernsey, 7 December 2023 Volta Finance Limited ("the Company") hereby announces that it has declared a quarterly interim dividend of €0.135 per share payable on 25 January 2024 amounting to approximately €4.94 million, approximately equating to an annualised 8.25% of net asset value. The ex-dividend date is 21 December 2023 with a record date of 22 December 2023. The Company has arranged for its shareholders to be able to elect to receive their dividends in either Euros or Pounds Sterling. Shareholders will, by default, receive their dividends in Euros, unless they have instructed the Company’s Registrar, Computershare Investor Services (Guernsey) Limited (“Computershare”), to pay dividends in Pounds Sterling. Such instructions may be given to Computershare either electronically via CREST or by using the Currency Election Form which has
Tag Systems and Fingerprint Cards AB (Fingerprints™) to bring biometric card to market7.12.2023 08:00:00 CET | Press release
Global card manufacturer Tag Systems (part of AUSTRIACARD Holdings AG) has achieved Mastercard certification for its biometric card based on Fingerprint Cards’ sensor and STMicroelectronics STPay-Topaz-Bio solution. Banks and fintechs can now issue Mastercard-branded biometric payment cards to enhance convenience and security for cardholders. Roger Carrico, Vice President, Head of Sales & Business development, Payment & Access at Fingerprints comments: “In Tag Systems we have a partner that likes to lead the way with high-end payment services. Banks and fintechs can take advantage of the opportunity to differentiate, retain and acquire customers and drive revenues.” Jon Neeraas, CEO at Tag Systems adds: “With this certification, we are excited to support our partners in issuing top-of-wallet biometric cards that utilize Fingerprints and ST latest technologies. Together, we are creating convenient, hygienic, and secure transactions for all purchases.” Following a partnership agreement i
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial7.12.2023 08:00:00 CET | Press release
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decadesMC2-25 CKD uses a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skinMC2-25 CKD has the potential to become the world’s first approved treatment for pre-dialysis Chronic Kidney Disease-associated Pruritus (CKD-aP), a debilitating condition thought to affect a significant proportion of the ~800 million people globally who suffer from Chronic Kidney Disease (CKD)111 patients enrolled in the multi-center trial across Europe with topline results expected in Q2 2024 Copenhagen, December 7th, 2023 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory conditions,